Immunic AG | Finanzwire

Basculer en Français

9475	Companies
185441	Keywords
117777	Articles
99294	Press releases

Home
Companies
Immunic AG

BRIEF

published on 10/29/2024 at 11:35, 1 year 1 month ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic
PRESS RELEASE

published on 10/29/2024 at 11:30, 1 year 1 month ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific
BRIEF

published on 10/22/2024 at 12:35, 1 year 1 month ago

Immunic Reports Positive Interim Results for Phase 3 ENSURE Program

Biotechnology Vidofludimus Calcium Phase 3 Trials Relapsing Multiple Sclerosis Interim Analysis
PRESS RELEASE

published on 10/22/2024 at 12:30, 1 year 1 month ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 3 ENSURE Program
BRIEF

published on 09/18/2024 at 12:35, 1 year 2 months ago

Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Multiple Sclerosis Immunic Vidofludimus Calcium Neuroprotection ECTRIMS 2024
PRESS RELEASE

published on 09/18/2024 at 12:30, 1 year 2 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark

Multiple Sclerosis Immunic Vidofludimus Calcium Therapeutic Potential ECTRIMS
BRIEF

published on 09/04/2024 at 12:35, 1 year 3 months ago

Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome

Clinical Trial Vidofludimus Calcium Post COVID Syndrome Fatigue Treatment Epstein-Barr Virus
PRESS RELEASE

published on 09/04/2024 at 12:30, 1 year 3 months ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic announces enrollment of the first patient in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium for Post COVID Syndrome. Study aims to suppress EBV reactivation and fatigue symptoms

Clinical Trial Immunic Vidofludimus Calcium Phase 2 Post COVID Syndrome
BRIEF

published on 08/28/2024 at 12:35, 1 year 3 months ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Multiple Sclerosis Immunic Vidofludimus Calcium R&D Day Scientific Conferences
PRESS RELEASE

published on 08/28/2024 at 12:30, 1 year 3 months ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Immunic to host Multiple Sclerosis R&D Day & participate in conferences. Immunic, Inc. develops oral therapies for autoimmune diseases

Investor Conferences Multiple Sclerosis Immunic R&D Day Scientific Conferences

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 25 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 30 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 55 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 10:30, 30 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 45 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 20 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 30 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 55 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 15 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 15 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 16 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE